Clinical Trial Update: Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and efficacy of adalimumab (Humira) for hidradenitis suppurativa peri-surgically has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie | Conditions: Hidradenitis Suppurativa (HS) | Phase 4 | Status: COMPLETED | Results posted: 2020-05-14